Understanding Mania and Bipolar Disorder

Somewhere between the cultural romanticization of mania — the brilliant, sleepless artist — and the clinical reality of a dangerous psychiatric emergency lies the truth of bipolar disorder. Mania can produce periods of apparent superhuman energy, creative fluency, and expansive confidence. It can also produce catastrophic decision-making, broken relationships, financial ruin, and, when mixed with depressive elements, elevated suicide risk. Understanding what mania actually is neurologically and clinically is essential for anyone affected by bipolar disorder, whether directly or through someone they care about.

What Is a Manic Episode?

A manic episode is defined by a distinct period of abnormally and persistently elevated, expansive, or irritable mood, accompanied by increased goal-directed activity or energy, lasting at least one week (or any duration if hospitalization is required). To meet the DSM-5 diagnostic threshold, at least three of the following symptoms must be present (four if mood is only irritable rather than elevated):

Grandiosity: Inflated self-esteem, unrealistically elevated sense of ability or importance
Decreased need for sleep: Feeling rested after as little as 2–3 hours; this is distinct from insomnia — the person does not feel tired
Pressured speech: Talking more than usual, difficulty being interrupted, rapid and difficult to follow
Racing thoughts/flight of ideas: Thoughts moving faster than they can be expressed, jumping between loosely connected ideas
Distractibility: Attention easily captured by external stimuli; inability to filter irrelevant information
Increased goal-directed activity or psychomotor agitation: Initiating multiple projects, increased social or sexual activity, physical restlessness
Risky behavior: Impulsive spending, sexual indiscretions, poor business investments, reckless driving

Crucially, the episode must represent a clear change from baseline behavior, observable by others, and cause marked functional impairment or necessitate hospitalization. Manic episodes are not simply “good moods.”

Bipolar I vs. Bipolar II

Bipolar I disorder requires at least one manic episode meeting the criteria above. Major depressive episodes are common but not required for the diagnosis. Psychotic features — delusions, hallucinations — are present in a significant minority of manic episodes in bipolar I, which can complicate diagnosis by resembling schizophrenia.

Bipolar II disorder involves hypomanic episodes (a less severe form of mania lasting at least four days, not requiring hospitalization, not featuring psychosis) plus at least one major depressive episode. Bipolar II is not simply “milder” bipolar I — the depressive burden is often greater, and accurate diagnosis is critical because treatment differs substantially.

Cyclothymic disorder involves numerous periods of hypomanic symptoms and depressive symptoms over at least two years that do not meet full criteria for hypomanic or major depressive episodes.

A common diagnostic pitfall is that patients with bipolar disorder typically present to clinicians during depressive episodes, not manic ones. Prescribing antidepressants without mood stabilizers in unrecognized bipolar disorder can precipitate mania or accelerate cycling — making accurate diagnosis a significant clinical priority.

The Neurochemistry of Mania

No single neurotransmitter system explains mania, and the neuroscience remains incompletely characterized. Several mechanisms are implicated:

Dopamine: Elevated dopaminergic activity in mesolimbic circuits is the most consistent neurochemical finding. Dopamine’s role in motivation, reward salience, and goal pursuit — when overactivated — maps directly onto the behavioral features of mania: elevated motivation, reduced inhibition, inflated goal-directed activity. The most effective anti-manic agents (antipsychotics) are potent dopamine D2 receptor blockers, supporting dopamine’s central role.

Norepinephrine: Elevated noradrenergic tone contributes to the arousal, reduced sleep need, and heightened reactivity of manic states. This also explains why medications that increase norepinephrine (stimulants, SNRIs, tricyclic antidepressants) can precipitate mania in vulnerable individuals.

Glutamate and GABA Imbalance: Evidence suggests excess excitatory glutamatergic activity and/or reduced GABAergic inhibition during mania. Valproate’s mood-stabilizing effect involves GABAergic enhancement among other mechanisms.

Circadian and Sleep Dysregulation: Mania is deeply intertwined with sleep-wake disruption. Sleep deprivation can precipitate mania in bipolar patients, and one of the earliest warning signs of an emerging manic episode is a progressive decrease in sleep without a corresponding increase in fatigue. The relationship between bipolar disorder and circadian rhythm abnormalities is an active research area.

The connection to anxiety disorders is also clinically significant — mixed states in bipolar disorder frequently include anxiety features, and misdiagnosis of bipolar disorder as an anxiety disorder delays appropriate mood stabilization.

Mood Stabilizers

Lithium

Lithium remains the gold-standard mood stabilizer after more than 70 years of clinical use, with the broadest evidence base for bipolar disorder. Its mechanism involves multiple interacting pathways — inhibition of inositol monophosphatase and glycogen synthase kinase-3 (GSK-3β), modulation of neurotrophic factors including BDNF, and regulation of circadian gene expression.

Lithium reduces both manic and depressive episodes and — uniquely among bipolar treatments — has demonstrated significant anti-suicide effects in large observational studies.

Its limitations are significant: a narrow therapeutic window (0.6–1.2 mEq/L for long-term maintenance), requirement for regular blood level monitoring, and a range of adverse effects including tremor, polyuria, weight gain, and thyroid/renal effects with long-term use. Toxicity above 1.5 mEq/L produces serious neurological effects. Dosing requires individualization, and patients require education about factors affecting lithium levels (hydration, sodium intake, NSAIDs, diuretics).

Valproate (Valproic Acid / Divalproex)

Valproate is effective for acute mania and long-term maintenance, with particular utility in rapid cycling and mixed states where lithium is less effective. Mechanisms include sodium channel stabilization, GABA enhancement, and GSK-3β inhibition.

It is generally better tolerated than lithium on a day-to-day basis, though it carries risks including weight gain, sedation, tremor, hair loss, and — critically — teratogenicity. Valproate is contraindicated in pregnancy due to significant risk of neural tube defects and cognitive effects in the exposed child. Hepatic function monitoring is required.

Lamotrigine

Lamotrigine is unusual among mood stabilizers in its asymmetric efficacy profile: it is effective for bipolar depression and maintenance (reducing depressive episodes) but has weaker evidence for acute mania. It is therefore most useful as a maintenance medication after acute mania has been treated, or in bipolar II where depression predominates.

Lamotrigine requires very slow dose titration to minimize the risk of serious rash, including Stevens-Johnson syndrome. When titration is followed carefully, it is one of the better-tolerated long-term mood stabilizers with a neutral weight profile.

Atypical Antipsychotics in Bipolar Disorder

Several atypical antipsychotics have FDA approvals for bipolar disorder — olanzapine, quetiapine, aripiprazole, risperidone, asenapine, and lurasidone among them. Their acute anti-manic efficacy is generally faster than mood stabilizers (lithium and valproate take 1–2 weeks for full effect), making them essential in acute inpatient settings.

Quetiapine has approvals for both acute mania and bipolar depression, giving it a broad profile in bipolar management. It is also commonly used off-label as a sleep aid in bipolar patients given its sedating properties.

Lurasidone is particularly notable for bipolar depression — it is one of very few agents with evidence for treating the depressive phase specifically, which is often the most disabling aspect of bipolar II.

The metabolic effects of atypical antipsychotics (weight gain, glucose dysregulation, lipid changes) vary by agent and require metabolic monitoring with long-term use.

Recognizing Warning Signs

Early identification of an emerging manic episode is one of the most valuable skills in bipolar disorder management, as intervention early in an episode is far more effective than waiting for full escalation. Common prodromal warning signs include:

Sleep changes: Needing less sleep without feeling tired is often the first signal
Increased goal-directed activity: Taking on new projects, making big plans
Elevated or irritable mood shift from the individual’s normal baseline
Increased talking speed or volume
Decreased judgment — spending decisions, social behavior, driving
Reduced response to usual coping strategies

Many patients and their support networks benefit from developing individualized “mood charts” and written relapse prevention plans that specify early warning signs, agreed-upon response actions, and emergency contacts.

The Intersection with Sleep

Insomnia is both a symptom and a trigger in bipolar disorder. Managing sleep carefully during stressful periods, jet lag, or shift changes is a concrete, actionable aspect of relapse prevention. Sleep regularization — consistent bed and wake times regardless of mood state — is recommended as a behavioral cornerstone of bipolar management, even between episodes.

Living with Bipolar Disorder

Bipolar disorder is a lifelong condition, but it is highly treatable. With appropriate pharmacotherapy, psychoeducation, and psychotherapy (particularly IPSRT — interpersonal and social rhythm therapy — which targets circadian stabilization), most people with bipolar disorder can achieve sustained periods of stability and functional engagement.

The goal of treatment is not the elimination of all mood variability — normal emotional range is preserved and healthy — but the prevention of episodes severe enough to impair functioning, damage relationships, or create risk.

Understanding comorbid conditions is also essential: anxiety disorders, substance use disorders, ADHD, and metabolic syndrome co-occur at higher rates in bipolar disorder and require coordinated management alongside mood stabilization. Sleep disruption — both as a prodrome and a consequence of mood episodes — makes attention to insomnia management a central component of long-term care.

The International Society for Bipolar Disorders (ISBD) publishes clinical practice guidelines and patient resources updated to current evidence.